[
  {
    "trial": "T009",
    "source": "library",
    "arms": {
      "Ketamine": {"randomized": "26", "analysed": "26"},
      "Placebo (0.9% saline)": {"randomized": "26", "analysed": "26"}
    },
    "depression": [
      {"measure": "Geriatric Depression Scale 15-item", "day": -1, "form": "median_iqr", "location": "Table 3",
       "values": {"Ketamine": {"median": "3", "q1": "0", "q3": "4", "n": "26"},
                  "Placebo (0.9% saline)": {"median": "2", "q1": "0", "q3": "3", "n": "26"}}},
      {"measure": "Geriatric Depression Scale 15-item", "day": 7, "form": "median_iqr", "location": "Table 3",
       "values": {"Ketamine": {"median": "2", "q1": "1", "q3": "3", "n": "26"},
                  "Placebo (0.9% saline)": {"median": "2", "q1": "1", "q3": "2", "n": "26"}}}
    ],
    "pain": [
      {"measure": "Morphine consumption (mg)", "day": 1, "form": "median_iqr", "location": "Table 2",
       "values": {"Ketamine": {"median": "15", "q1": "8", "q3": "22", "n": "26"},
                  "Placebo (0.9% saline)": {"median": "15", "q1": "8", "q3": "24", "n": "26"}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2007-02", "end": "2008-03"},
    "registration": null,
    "note": "GDS-15 (Table 3) is median (interquartile range), n = 26 per column. The 1-week test was 1 week after surgery or at discharge, whichever came first (coded day 7). Table 3's cells come through as PDF text blocks; I read them in the header's column order (placebo, ketamine, nonsurgical control at baseline, then the same at 1 week), which fits the Discussion (ketamine scores stable, nonsurgical controls improving). The design lists no pain measure; Table 2's morphine consumption on postoperative day 1 (mg, median (IQR)) is coded at day 1 under the source's name; day-of-surgery morphine (placebo 20 (10–24), ketamine 15 (10–20)) is day 0 and left out. No psychotomimetic adverse events reported. The nonsurgical control group (n = 26, not randomized) is left out."
  },
  {
    "trial": "T041",
    "source": "fulltext",
    "arms": {
      "Group E": {"randomized": "142", "analysed": "108"},
      "Group C": {"randomized": "142", "analysed": "101"}
    },
    "depression": [
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": -1, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3",
       "values": {"Group E": {"events": "32", "n": "108"}, "Group C": {"events": "37", "n": "101"}}},
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": 3, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3",
       "values": {"Group E": {"events": "55", "n": "102"}, "Group C": {"events": "67", "n": "99"}}},
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": 7, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3",
       "values": {"Group E": {"events": "26", "n": "99"}, "Group C": {"events": "46", "n": "96"}}},
      {"measure": "Hamilton Depression Scale 17 (HAMD-17)", "day": 90, "form": "count", "definition": "HAMD-17 ≥ 7", "location": "Table 3",
       "values": {"Group E": {"events": "11", "n": "83"}, "Group C": {"events": "25", "n": "88"}}}
    ],
    "pain": [
      {"measure": "Postoperative exercise NRS score", "day": 1, "form": "mean_sd", "location": "Table 4",
       "values": {"Group E": {"mean": "2.67", "sd": "0.97", "n": "108"}, "Group C": {"mean": "2.84", "sd": "0.86", "n": "101"}}},
      {"measure": "Postoperative exercise NRS score", "day": 2, "form": "mean_sd", "location": "Table 4",
       "values": {"Group E": {"mean": "2.25", "sd": "1.00", "n": "108"}, "Group C": {"mean": "2.46", "sd": "0.88", "n": "101"}}}
    ],
    "adverse_events": [
      {"window": "postoperative",
       "values": {"Group E": {"dizziness": "16", "nightmare": "3", "hallucination": "0"},
                  "Group C": {"dizziness": "10", "nightmare": "1", "hallucination": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2022-08", "end": "2023-08"},
    "registration": {"registry": "Chinese Clinical Trial Registry", "number": "ChiCTR2300069249", "date": null},
    "note": "Randomized: the Results say 284 signed consent, 142 in each group (the flowchart is not in the text); analysed = the column Ns of Tables 1 and 4 (108, 101) after early withdrawals. HAMD-17 is reported only as counts of depressive symptoms (HAMD-17 ≥ 7) in Table 3, each time with its own denominator; HAMD scores are only plotted (Figure 3, no printed values). Pain: the design lists none; Table 4 reports NRS on movement ('postoperative exercise NRS score', mean (SD)) on postoperative days 1 to 3, coded at days 1 and 2 under the source's name with the table's column Ns; pump presses and dezocine rescue are not pain scores and are left out. Adverse events are Table 5's postoperative in-hospital events. Enrollment is from Methods (study carried out 1 August 2022 to 30 August 2023); the Results give no dates. Registration number given without a date."
  },
  {
    "trial": "T049",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "78", "analysed": "75"},
      "Normal saline group": {"randomized": "78", "analysed": "76"}
    },
    "depression": [
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": -1, "form": "count", "definition": "BDI-II ≥ 14 (0–13 absent)", "location": "Table 1",
       "values": {"Esketamine group": {"events": "0", "n": "78"}, "Normal saline group": {"events": "2", "n": "78"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 2, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "6", "q1": "5", "q3": "8", "n": "78"}, "Normal saline group": {"median": "6", "q1": "5", "q3": "8", "n": "78"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 2, "form": "count", "definition": "BDI-II ≥ 14 (0–13 absent)", "location": "Table 3",
       "values": {"Esketamine group": {"events": "0", "n": "78"}, "Normal saline group": {"events": "1", "n": "78"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 30, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "5", "q1": "4", "q3": "7", "n": "75"}, "Normal saline group": {"median": "5", "q1": "4", "q3": "8", "n": "76"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 30, "form": "count", "definition": "BDI-II ≥ 14 (0–13 absent)", "location": "Table 3",
       "values": {"Esketamine group": {"events": "1", "n": "75"}, "Normal saline group": {"events": "9", "n": "76"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 90, "form": "median_iqr", "location": "Table 3",
       "values": {"Esketamine group": {"median": "1.5", "q1": "0", "q3": "4", "n": "74"}, "Normal saline group": {"median": "2", "q1": "0", "q3": "5", "n": "76"}}},
      {"measure": "Beck Depression Inventory-II (BDI-II)", "day": 90, "form": "count", "definition": "BDI-II ≥ 14 (0–13 absent)", "location": "Table 3",
       "values": {"Esketamine group": {"events": "0", "n": "74"}, "Normal saline group": {"events": "1", "n": "76"}}}
    ],
    "pain": [
      {"measure": "VAS at rest", "day": 1, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "0", "q1": "0", "q3": "1", "n": "78"}, "Normal saline group": {"median": "0", "q1": "0", "q3": "1", "n": "78"}}},
      {"measure": "VAS at rest", "day": 2, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "0", "q1": "0", "q3": "1", "n": "78"}, "Normal saline group": {"median": "0", "q1": "0", "q3": "0", "n": "78"}}},
      {"measure": "VAS on coughing", "day": 1, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "3", "q1": "0", "q3": "5", "n": "78"}, "Normal saline group": {"median": "3", "q1": "2", "q3": "5", "n": "78"}}},
      {"measure": "VAS on coughing", "day": 2, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "6", "n": "78"}, "Normal saline group": {"median": "3", "q1": "2", "q3": "4", "n": "78"}}},
      {"measure": "PCIA sufentanil consumption 0-24 and 0-48 h", "day": 1, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "42.2", "q1": "37.8", "q3": "52.5", "n": "78"}, "Normal saline group": {"median": "42", "q1": "38.5", "q3": "49.3", "n": "78"}}},
      {"measure": "PCIA sufentanil consumption 0-24 and 0-48 h", "day": 2, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "87.8", "q1": "77.1", "q3": "101.6", "n": "78"}, "Normal saline group": {"median": "85.2", "q1": "78.1", "q3": "99.4", "n": "78"}}}
    ],
    "adverse_events": [
      {"window": "postoperative",
       "values": {"Esketamine group": {"nightmare": "1", "dizziness": "18", "visual": "1", "dissociation": "0"},
                  "Normal saline group": {"nightmare": "4", "dizziness": "17", "visual": "2", "dissociation": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2021-05", "end": "2022-05"},
    "registration": {"registry": "Chinese Clinical Trial Registry", "number": null, "date": "2021-05-09"},
    "note": "BDI-II scores (Table 3) are median (IQR); the 48-h rows print no n of their own, so they carry the column n = 78, while the 1- and 3-month rows print theirs. Depressive symptoms = BDI-II of 14 or more (0–13 absent, per Methods). Day 30 counts are the modified ITT population (after excluding patients without lung cancer: 1/72 vs 9/74). BDI-II at hospital discharge has no fixed day (median postoperative stay 4 and 5 days), so it is not coded: score 6 (5, 7) vs 6 (5, 8), depressive symptoms 0 vs 4 (5.1%), esketamine vs saline. No baseline BDI-II score is reported, only the count of depressive symptoms 1 day before surgery (Table 1). Pain (Table 2) is median (IQR) with column n = 78; sufentanil 0–24 h is coded at day 1 and 0–48 h at day 2 (cumulative, μg). Adverse events are within 0–48 h after surgery (Table 2); blurred vision coded as visual; delirium (0 vs 0) not coded. Registered with the Chinese Clinical Trial Registry on 9 May 2021, before the first enrolment; the number is not in the text."
  },
  {
    "trial": "T053",
    "source": "fulltext",
    "arms": {
      "Group S": {"randomized": null, "analysed": "53"},
      "Group P": {"randomized": null, "analysed": "53"}
    },
    "depression": [
      {"measure": "Hamilton Depression Scale (HAMD)", "day": -1, "form": "mean_sd", "location": "Table 3",
       "values": {"Group S": {"mean": "10.0", "sd": "2.8", "n": null}, "Group P": {"mean": "9.6", "sd": "3.0", "n": null}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 3, "form": "mean_sd", "location": "Table 3",
       "values": {"Group S": {"mean": "9.0", "sd": "1.8", "n": null}, "Group P": {"mean": "9.3", "sd": "2.9", "n": null}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 7, "form": "mean_sd", "location": "Table 3",
       "values": {"Group S": {"mean": "9.8", "sd": "1.6", "n": null}, "Group P": {"mean": "9.1", "sd": "2.7", "n": null}}},
      {"measure": "Hamilton Depression Scale (HAMD)", "day": 30, "form": "mean_sd", "location": "Table 3",
       "values": {"Group S": {"mean": "9.8", "sd": "2.6", "n": null}, "Group P": {"mean": "10.0", "sd": "3.0", "n": null}}}
    ],
    "pain": [
      {"measure": "NRS pain", "day": 1, "form": "median_iqr", "location": "Table 3",
       "values": {"Group S": {"median": "2", "q1": "2", "q3": "4", "n": null}, "Group P": {"median": "3", "q1": "2", "q3": "4.5", "n": null}}},
      {"measure": "NRS pain", "day": 2, "form": "median_iqr", "location": "Table 3",
       "values": {"Group S": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Group P": {"median": "2", "q1": "1", "q3": "3", "n": null}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2022-04", "end": "2022-07"},
    "registration": {"registry": "Chinese Clinical Trial Registry", "number": "ChiCTR2100049857", "date": null},
    "note": "118 women enrolled; 4 (surgery cancelled) and 8 (changed surgical modality) were excluded, leaving 53 per group; the numbers randomized per group are only in Figure 1 (not in the text). Table 3 gives no n per time point. HAMD (mean ± SD) at 72 h coded as day 3; the 7- and 30-day values were collected by telephone. NRS pain (Table 3) is median (IQR): 24 h coded day 1, 48 h day 2; the 8-h, 72-h, 7-day and 30-day values and the NRS 10 min after extubation (Table 2) fall outside the pain days. Adverse reactions are only in Table S1, not in the text. Enrollment is from Methods (recruited April to July 2022). Registered before enrolment; no date given."
  },
  {
    "trial": "T065",
    "source": "fulltext",
    "arms": {
      "Esketamine group (Group E)": {"randomized": "32", "analysed": "32"},
      "Control group (Group C)": {"randomized": "32", "analysed": "32"}
    },
    "depression": [
      {"measure": "PHQ-9", "day": -1, "form": "mean_sd", "location": "Table 3",
       "values": {"Esketamine group (Group E)": {"mean": "3.22", "sd": "3.44", "n": null}, "Control group (Group C)": {"mean": "3.28", "sd": "3.15", "n": null}}},
      {"measure": "PHQ-9", "day": 1, "form": "mean_sd", "location": "Table 3",
       "values": {"Esketamine group (Group E)": {"mean": "2.19", "sd": "2.75", "n": null}, "Control group (Group C)": {"mean": "4.03", "sd": "3.84", "n": null}}},
      {"measure": "PHQ-9", "day": 3, "form": "mean_sd", "location": "Table 3",
       "values": {"Esketamine group (Group E)": {"mean": "2.56", "sd": "3.27", "n": null}, "Control group (Group C)": {"mean": "3.25", "sd": "2.71", "n": null}}},
      {"measure": "PHQ-9", "day": 7, "form": "mean_sd", "location": "Table 3",
       "values": {"Esketamine group (Group E)": {"mean": "1.91", "sd": "2.26", "n": null}, "Control group (Group C)": {"mean": "3.16", "sd": "2.94", "n": null}}},
      {"measure": "PHQ-9", "day": 30, "form": "mean_sd", "location": "Table 3",
       "values": {"Esketamine group (Group E)": {"mean": "1.72", "sd": "2.05", "n": null}, "Control group (Group C)": {"mean": "2.44", "sd": "2.94", "n": null}}}
    ],
    "pain": [
      {"measure": "VAS pain score", "day": 1, "form": "mean_sd", "location": "Table 3",
       "values": {"Esketamine group (Group E)": {"mean": "1.28", "sd": "1.97", "n": null}, "Control group (Group C)": {"mean": "1.22", "sd": "1.70", "n": null}}}
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {"start": "2022-05", "end": "2023-03"},
    "registration": null,
    "note": "Table 3 prints mean ± SD (Methods: quantitative data as mean ± SD; Figures 4 and 5 plot mean and SE), so coded mean_sd. Table 3 gives no n; 32 per group were analysed and the Results say no one missed follow-up. 'Before' coded as baseline. Pain: only the POD 1 VAS falls on the pain days (POD 3, 7, 30 left out); the design's opioid measure, intraoperative remifentanil (Table 2), is day 0 and left out. Complications (Table 2) were nausea, vomiting and delirium (0 vs 0), none in the adverse-event categories. Enrollment is from Methods (patients operated May 2022 to March 2023). No registration in the text."
  },
  {
    "trial": "T081",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "71", "analysed": "71"},
      "Saline control group": {"randomized": "71", "analysed": "71"}
    },
    "depression": [
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": -1, "form": "count", "definition": "HADS-D ≥ 8 (0–7 normal)", "location": "Table 2",
       "values": {"Esketamine group": {"events": "26", "n": "71"}, "Saline control group": {"events": "25", "n": "71"}}},
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": 7, "form": "count", "definition": "HADS-D ≥ 8 (0–7 normal)", "location": "Table 3",
       "values": {"Esketamine group": {"events": "5", "n": "71"}, "Saline control group": {"events": "22", "n": "71"}}},
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": 7, "form": "difference", "location": "Results 3.2, text",
       "estimate": "1.61", "lower": "0.40", "upper": "2.82", "level": "0.95", "scale": "mean_difference",
       "comparison": "Saline control group minus Esketamine group",
       "values": {"Esketamine group": {"n": null}, "Saline control group": {"n": null}}},
      {"measure": "HADS depression subscale (HADS-D, Chinese HADS)", "day": 30, "form": "count", "definition": "HADS-D ≥ 8 (0–7 normal)", "location": "Table 3",
       "values": {"Esketamine group": {"events": "0", "n": "71"}, "Saline control group": {"events": "3", "n": "71"}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "postoperative",
       "values": {"Esketamine group": {"psychiatric_any": "13", "visual": "1"},
                  "Saline control group": {"psychiatric_any": "6", "visual": "0"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-09", "end": "2025-03"},
    "registration": {"registry": "ClinicalTrials.gov", "number": "NCT06608030", "date": null},
    "note": "Baseline depression: Table 2 gives control 25 (35.2) and esketamine 26 (36.6), but the Results text gives 25/71 for esketamine and 26/71 for controls; took the table's. Depression = HADS-D of 8 or more (0–7 normal, per Methods). n = 71 per group is the ITT population (4 per group lost the primary endpoint; per-protocol results are in Table S3). HADS-D scores appear only as a post hoc mixed-model difference at POD 7: MD 1.61 (SEM 0.61), 95% CI 0.40 to 2.82, Sidak-adjusted, the esketamine group lower (control minus esketamine); arm ns not given. 'Reduction of HADS score ≥ 2 / ≥ 50% from baseline' (Table 3) is not HADS-D alone and is not coded. Pain: NRS only at POD 7 and POD 30, none at days 1 to 2. Adverse events are drug-related side effects within 3 days (Table 4): 'Hallucination or nightmares' is one combined count, coded psychiatric_any; 'Nystagmus, blurred vision' coded visual. Delirium within 7 days (control 16, esketamine 7; hyperactive 4 vs 2) is an efficacy outcome and is not coded as agitation. Enrollment is from Methods (enrolled September 2024 to March 2025; first patient 23 September 2024). Registered before enrolment; no date given."
  },
  {
    "trial": "T089",
    "source": "fulltext",
    "arms": {
      "Esk group": {"randomized": "44", "analysed": "41"},
      "NS group": {"randomized": "44", "analysed": "41"}
    },
    "depression": [
      {"measure": "HAMD-17", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Esk group": {"median": "6", "q1": "5", "q3": "7", "n": "41"}, "NS group": {"median": "6", "q1": "5", "q3": "7", "n": "41"}}},
      {"measure": "HAMD-17", "day": 7, "form": "median_iqr", "location": "Table 2",
       "values": {"Esk group": {"median": "7", "q1": "6", "q3": "8", "n": "41"}, "NS group": {"median": "7", "q1": "6", "q3": "12", "n": "41"}}},
      {"measure": "HAMD-17", "day": 30, "form": "median_iqr", "location": "Table 2",
       "values": {"Esk group": {"median": "6", "q1": "6", "q3": "7", "n": "41"}, "NS group": {"median": "7", "q1": "6", "q3": "9", "n": "41"}}}
    ],
    "pain": [
      {"measure": "NRS at rest (24, 48 h)", "day": 1, "form": "median_iqr", "location": "Table 4",
       "values": {"Esk group": {"median": "2", "q1": "0", "q3": "2", "n": "41"}, "NS group": {"median": "2", "q1": "0", "q3": "3", "n": "41"}}},
      {"measure": "NRS at rest (24, 48 h)", "day": 2, "form": "median_iqr", "location": "Table 4",
       "values": {"Esk group": {"median": "0", "q1": "0", "q3": "1", "n": "41"}, "NS group": {"median": "0", "q1": "0", "q3": "1", "n": "41"}}},
      {"measure": "NRS on coughing (24, 48 h)", "day": 1, "form": "median_iqr", "location": "Table 4",
       "values": {"Esk group": {"median": "3", "q1": "1", "q3": "4", "n": "41"}, "NS group": {"median": "3", "q1": "1", "q3": "4", "n": "41"}}},
      {"measure": "NRS on coughing (24, 48 h)", "day": 2, "form": "median_iqr", "location": "Table 4",
       "values": {"Esk group": {"median": "1", "q1": "0", "q3": "2", "n": "41"}, "NS group": {"median": "1", "q1": "0", "q3": "3", "n": "41"}}}
    ],
    "adverse_events": [
      {"window": "postoperative",
       "values": {"Esk group": {"psychiatric_any": "1", "agitation": "0", "dizziness": "3"},
                  "NS group": {"psychiatric_any": "1", "agitation": "1", "dizziness": "2"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-08", "end": "2024-06"},
    "registration": null,
    "note": "88 randomized, 44 per group (Methods 1.1); 3 per group excluded after randomization, 41 per group analysed. HAMD-17 is median (P25, P75), n = 41 per column; baseline was 1 day before surgery. HAMD-17 ≥ 8 defines depression, but no counts are reported. Pain NRS (Table 4, n = 41 per group) at 24 h and 48 h. Adverse events (Table 4, postoperative): 'Hallucination or nightmare' is one combined count, coded psychiatric_any; 'Headache or dizziness' is one combined count, coded dizziness although it includes headache; agitation as printed. Enrollment is from Methods (patients operated August 2023 to June 2024). No registration number in the text."
  },
  {
    "trial": "T095",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {"randomized": "154", "analysed": "154"},
      "Control group": {"randomized": "154", "analysed": "154"}
    },
    "depression": [
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": -1, "form": "median_iqr", "location": "Table 1",
       "values": {"Esketamine group": {"median": "5", "q1": "2", "q3": "10", "n": "154"}, "Control group": {"median": "5", "q1": "2", "q3": "9", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "count", "definition": "EPDS > 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "24", "n": "154"}, "Control group": {"events": "37", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 7, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "5", "q1": "1.75", "q3": "8", "n": "154"}, "Control group": {"median": "5", "q1": "3", "q3": "9", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "count", "definition": "EPDS > 10", "location": "Table 2",
       "values": {"Esketamine group": {"events": "16", "n": "154"}, "Control group": {"events": "30", "n": "154"}}},
      {"measure": "Edinburgh Postnatal Depression Scale (EPDS)", "day": 42, "form": "median_iqr", "location": "Table 2",
       "values": {"Esketamine group": {"median": "5", "q1": "2", "q3": "7", "n": "154"}, "Control group": {"median": "6", "q1": "3", "q3": "9", "n": "154"}}}
    ],
    "pain": [
      {"measure": "NRS at rest", "day": 1, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2A)",
       "values": {"Esketamine group": {"median": "1", "q1": "1", "q3": "2", "n": null}, "Control group": {"median": "1", "q1": "1", "q3": "2", "n": null}}},
      {"measure": "NRS at rest", "day": 2, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2A)",
       "values": {"Esketamine group": {"median": "1", "q1": "1", "q3": "1", "n": null}, "Control group": {"median": "1", "q1": "0.75", "q3": "1", "n": null}}},
      {"measure": "NRS with movement", "day": 1, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2B)",
       "values": {"Esketamine group": {"median": "3", "q1": "3", "q3": "3", "n": null}, "Control group": {"median": "3", "q1": "3", "q3": "3", "n": null}}},
      {"measure": "NRS with movement", "day": 2, "form": "median_iqr", "location": "Results, Efficacy Outcomes text (Figure 2B)",
       "values": {"Esketamine group": {"median": "2", "q1": "2", "q3": "3", "n": null}, "Control group": {"median": "2", "q1": "2", "q3": "3", "n": null}}}
    ],
    "adverse_events": [
      {"window": "intraoperative",
       "values": {"Esketamine group": {"dizziness": "28", "dissociation": "9", "hallucination": "4", "nightmare": "16", "visual": "1", "any_ae": "65"},
                  "Control group": {"dizziness": "3", "dissociation": "0", "hallucination": "0", "nightmare": "0", "visual": "0", "any_ae": "12"}}},
      {"window": "postoperative",
       "values": {"Esketamine group": {"dizziness": "8", "any_ae": "23"},
                  "Control group": {"dizziness": "5", "any_ae": "14"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2023-03", "end": "2024-02"},
    "registration": null,
    "note": "PPD counts use the primary definition, printed as EPDS > 10; but the sensitivity row 'EPDS score ≥11' gives different counts (1 wk 24 vs 31; 6 wk 13 vs 24) and the text calls 10 or higher the common cutoff, so the primary count may be EPDS ≥ 10. Other sensitivity counts (Table 2, esketamine vs control): ≥ 9: 1 wk 32 vs 41, 6 wk 26 vs 45; ≥ 12: 1 wk 15 vs 23, 6 wk 8 vs 18. Timing of the baseline EPDS (Table 1) is not stated; antenatal depression (42 vs 36, definition not given) is not coded. Pain values are printed in the Results text (Figure 2 has no printed values); n not given. PCIA consumption (75.55 [5.81] vs 76.40 [6.06] mL) and bolus use are totals, not at 24 or 48 h, and are left out. Adverse events (Table 3): 'At end of surgery' coded intraoperative (asked at the end of surgery; patients awake under neuraxial anesthesia; infusion after delivery); 'mental trance state' coded dissociation, 'dreamscape' (a dreamlike scene during surgery) coded nightmare, diplopia coded visual; 'Total' rows coded any_ae, though each equals the sum of its rows and may count events rather than patients. 'Within 3 d post partum' coded postoperative. From 3 d to 6 wk post partum (total 16 vs 9; anxiety 7 vs 2) not coded. Enrollment is from Methods (conducted March 2023 to February 2024). No registration number in the text."
  },
  {
    "trial": "T104",
    "source": "fulltext",
    "arms": {
      "N group (saline)": {"randomized": "35", "analysed": null},
      "A group (esketamine)": {"randomized": "35", "analysed": null}
    },
    "depression": [
      {"measure": "Zung SDS", "day": -1, "form": "mean_sd", "location": "Table 3",
       "values": {"N group (saline)": {"mean": "46.0", "sd": "8.7", "n": null}, "A group (esketamine)": {"mean": "46.0", "sd": "8.2", "n": null}}},
      {"measure": "Zung SDS", "day": 1, "form": "mean_sd", "location": "Table 3",
       "values": {"N group (saline)": {"mean": "52.5", "sd": "9.7", "n": null}, "A group (esketamine)": {"mean": "49.0", "sd": "8.8", "n": null}}},
      {"measure": "Zung SDS", "day": 2, "form": "mean_sd", "location": "Table 3",
       "values": {"N group (saline)": {"mean": "50.0", "sd": "9.0", "n": null}, "A group (esketamine)": {"mean": "47.5", "sd": "8.4", "n": null}}}
    ],
    "pain": [],
    "adverse_events": [
      {"window": "emergence",
       "values": {"N group (saline)": {"agitation": "11"}, "A group (esketamine)": {"agitation": "8"}}},
      {"window": "postoperative",
       "values": {"N group (saline)": {"psychiatric_any": "0"}, "A group (esketamine)": {"psychiatric_any": "5"}}}
    ],
    "blinding_check": null,
    "enrollment": {"start": "2024-05", "end": "2025-12"},
    "registration": null,
    "note": "Secondary analysis of a four-arm randomized study (LA, L, A, N; 35 each); L and LA left out. All 140 were in the safety analysis; efficacy used available cases and no SDS ns are given (QoR-40 POD1 available A 35, N 34; POD7 A 34, N 34), so analysed and n are null. Table columns run LA, L, A, N. SDS (standardized score, mean ± SD) at baseline was the day before surgery (Table 1 gives the same values); POD1 = 24 ± 6 h and POD2 = 48 ± 6 h after extubation. The QoR-40 pain dimension is only in Supplementary Table S1, so there are no pain entries. Emergence agitation = Riker ≥ 5 in PACU. 'Vivid dreams/hallucinations' (asked in PACU and on POD1) is one combined count, coded psychiatric_any. Nu-DESC PACU delirium-like symptoms (A 3, N 4) not coded. Blinding success was not assessed. Enrollment is from Methods (parent study May 2024 to December 2025). No registration in the text."
  }
]